Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 9:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Relapsing-remitting Multiple Sclerosis Clear all
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Midazolam, Caffeine, S-warfarin, Vitamin K, Omeprazole, Dextromethorphan, BIIB019 (Daclizumab)
Drug · Other · Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
7
States / cities
Centennial, Colorado • Washington D.C., District of Columbia • Lake Barrington, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced May 21, 2026, 9:40 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
Interferon-1beta (Betaseron, BAY86-5046)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 50 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Many Locations, Alabama • Many Locations, Arizona • Many Locations, Delaware + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2011 · Synced May 21, 2026, 9:40 PM EDT
Active, not recruiting Not applicable Interventional
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions
Glycemic load, Calorie restriction, Behavioral support
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Birmingham, Alabama • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced May 21, 2026, 9:40 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
Interventions
BIIB033, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Centennial, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced May 21, 2026, 9:40 PM EDT
Not yet recruiting Phase 2 Interventional
View directory record Official record
Conditions
Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive, Multiple Sclerosis (MS) Primary Progressive
Interventions
Remibrutinib (Open Label)
Drug
Lead sponsor
Moein Amin
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 21, 2026, 9:40 PM EDT
Not yet recruiting Not applicable Interventional
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting, Sexual Dysfunction
Interventions
Behavioural intervention for physical activity for multiple sclerosis (BIPAMS)
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced May 21, 2026, 9:40 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ELND002, Placebo
Drug
Lead sponsor
Elan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
17
States / cities
Berkeley, California • Fresno, California • Newport Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced May 21, 2026, 9:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
IFN-β-1a (Rebif®)
Drug
Lead sponsor
Waukesha Memorial Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Waukesha, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced May 21, 2026, 9:40 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
BIIB019 (Daclizumab High Yield Process), Interferon beta-1a Placebo, Interferon beta-1a, Daclizumab High Yield Process Placebo
Biological · Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
46
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2016 · Synced May 21, 2026, 9:40 PM EDT
Completed Phase 4 Interventional
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Donepezil HCI (drug)
Drug
Lead sponsor
Neurognostics
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 15, 2007 · Synced May 21, 2026, 9:40 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
RELAPSING REMITTING MULTIPLE SCLEROSIS
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced May 21, 2026, 9:40 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT)
Procedure · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
22
States / cities
Palo Alto, California • Aurora, Colorado • Evanston, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced May 21, 2026, 9:40 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
Swank Diet, Wahls Elimination Diet
Behavioral
Lead sponsor
Terry L. Wahls
Other
Eligibility
18 Years to 70 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced May 21, 2026, 9:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Acthar
Drug
Lead sponsor
OhioHealth
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced May 21, 2026, 9:40 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Rocky Mountain MS Research Group, LLC
Other
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced May 21, 2026, 9:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Ofatumumab
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced May 21, 2026, 9:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Glatiramer acetate
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced May 21, 2026, 9:40 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Interventions
Not listed
Lead sponsor
LAPIX Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Baltimore, Maryland • Chevy Chase, Maryland • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced May 21, 2026, 9:40 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Interferon beta-1b (Betaseron, BAY86-5046), BETACONNECT device
Drug · Device
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
23
States / cities
Cullman, Alabama • Boca Raton, Florida • New Port Richey, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced May 21, 2026, 9:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Blood Draw
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2017
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced May 21, 2026, 9:40 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Interferon beta 1-a, glatiramer acetate, placebo
Drug · Other
Lead sponsor
Fred Lublin
Other
Eligibility
18 Years to 60 Years
Enrollment
1,008 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
67
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced May 21, 2026, 9:40 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Belimumab, Short-course Ocrelizumab, Continued Ocrelizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced May 21, 2026, 9:40 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Interventions
Acute Intermittent Hypoxia, Neuromuscular Electrical Stimulation
Other
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced May 21, 2026, 9:40 PM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Fingolimod, Disease Modifying therapy
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
122
States / cities
Cullman, Alabama • Phoenix, Arizona • Sun City, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced May 21, 2026, 9:40 PM EDT